why choose us

300×250 Ad Slot

Research Article: Evaluation of Sulfasalazine as an Adjunctive Therapy in Treating Pulmonary Pre-XDR-TB: Efficacy, Safety, and Treatment Implication

Date Published: 2024-02-17

Abstract:
Tuberculosis (TB) remains a formidable global health challenge with Mycobacterium tuberculosis (M. tb) accounting for numerous deaths worldwide. A significant hurdle in TB control is drug resistance, notably multi-drug resistant tuberculosis (MDR-TB) and the emergent pre-extensively drug-resistant tuberculosis (pre-XDR-TB). MDR-TB is caused by strains resistant to at least isoniazid and rifampicin; Rifampicin-resistant TB (RR-TB) is specifically resistant to rifampicin. Pre-XDR-TB involves MDR/RR-TB strains also resistant to any fluoroquinolone (FQ); Extensively drug-resistant TB (XDR-TB) extends to MDR/RR-TB strains resistant to any FQ and at least one of bedaquiline (Bdq) or linezolid (Lzd). Treatment for MDR-TB typically spans to months using a combination of antimicrobials, while pre-XDR-TB demands even more extended treatment with a lower success rate (% vs % for MDR-TB). There’s an evident need for innovative therapeutic strategies.

Introduction:
Tuberculosis (TB) remains a formidable global health challenge with Mycobacterium tuberculosis (M. tb) accounting for numerous deaths worldwide. A significant hurdle in TB control is drug resistance, notably multi-drug resistant tuberculosis (MDR-TB) and the emergent pre-extensively drug-resistant tuberculosis (pre-XDR-TB). MDR-TB is caused by strains resistant to at least isoniazid and rifampicin; Rifampicin-resistant TB (RR-TB) is specifically resistant to rifampicin. Pre-XDR-TB involves MDR/RR-TB strains also…

Read more

300×250 Ad Slot